Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.
Human monocyte-derived DCs (moDCs) and circulating conventional DCs coexpress activating (CD32a) and inhibitory (CD32b) isoforms of IgG Fcgamma receptor (FcgammaR) II (CD32). The balance between these divergent receptors establishes a threshold of DC activation and enables immune complexes to mediate opposing effects on DC maturation and function. IFN-gamma most potently favors CD32a expression on immature DCs, whereas soluble antiinflammatory concentrations of monomeric IgG have the opposite effect. Ligation of CD32a leads to DC maturation, increased stimulation of allogeneic T cells, and enhanced secretion of inflammatory cytokines, with the exception of IL-12p70. Coligation of CD32b limits activation through CD32a and hence reduces the immunogenicity of moDCs even for a strong stimulus like alloantigen. Targeting CD32b alone does not mature or activate DCs but rather maintains an immature state. Coexpression of activating and inhibitory FcgammaRs by DCs reveals a homeostatic checkpoint for inducing tolerance or immunity by immune complexes. These findings have important implications for understanding the pathophysiology of immune complex diseases and for optimizing the efficacy of therapeutic mAbs. The data also suggest novel strategies for targeting antigens to the activating or inhibitory FcgammaRs on human DCs to generate either antigen-specific immunity or tolerance.
Boruchov
Adam M
AM
Laboratory of Cellular Immunobiology, Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. boruchoa@mskcc.org
Heller
Glenn
G
Veri
Maria-Concetta
MC
Bonvini
Ezio
E
Ravetch
Jeffrey V
JV
Young
James W
JW
D000936:Antigen-Antibody Complex / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology*; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology / Q000378:metabolism*; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007105:Immune Complex Diseases / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D007074:Immunoglobulin G / Q000276:immunology* / Q000494:pharmacology; D007249:Inflammation / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism*; D018664:Interleukin-12 / Q000276:immunology / Q000378:metabolism*; D007519:Isoantigens / Q000276:immunology; D008213:Lymphocyte Activation; D009000:Monocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D017452:Receptors, IgG / Q000276:immunology*; D013601:T-Lymphocytes
D000936:Antigen-Antibody Complex; D015703:Antigens, CD; C080568:Fc gamma receptor IIA; C080571:Fc gamma receptor IIB; D007074:Immunoglobulin G; D007519:Isoantigens; D017452:Receptors, IgG; D018664:Interleukin-12; D007371:Interferon-gamma